title: New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study.
abstract: The objective of this study was to clarify the incidence, clinical characteristics, and courses of new-onset psychiatric manifestations after corticosteroid therapy in patients with systemic lupus erythematosus (SLE), including possible ways of differentiating between corticosteroid-induced psychiatric disorders (CIPDs) and central nervous system manifestations of SLE (CNS-SLE). We prospectively followed for 8 weeks 139 consecutive episodes in 135 in-patients who had a non-CNS-SLE flare treated with corticosteroids. Psychiatric events were evaluated once a week using DSM-IV criteria. We then conducted a post hoc etiological analysis of any newly developed psychiatric events during this follow-up period. In the 8 weeks of corticosteroid administration, new psychiatric events occurred in 20 (14.4 %) of the 139 episodes. The mean dosage of corticosteroids administered was prednisolone at 0.98 (range 0.24-1.39) mg/kg/day. Of the 20 psychiatric events, 14 (10.1 %) were suitable for the strict definition of CIPDs, accompanied by mood disorders in 13 (depressive in 2, manic in 9, and mixed in 2) and psychotic disorder in one. Two (1.4 %), both presenting delirium, were diagnosed as CNS-SLE on the basis of evidence of abnormal CNS findings even before psychiatric manifestations, all of which improved in parallel with these patients' recoveries through augmentation of immunosuppressive therapy. The other four events (2.9 %) could not be etiologically identified. This study suggests that corticosteroid therapy triggers CIPDs and CNS-SLE in patients with SLE. Delirium may be suggestive of CNS-SLE, while mood disorders may be more suggestive of CIPDs. Electroencephalographic abnormalities may possibly be predictive of CNS-SLE.
authors.affiliation: Department of Psychiatry, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan, nishimura.katsuji@twmu.ac.jp.
authors.forename: Katsuji
authors.initials: K
authors.lastname: Nishimura
authors.forename: Masako
authors.initials: M
authors.lastname: Omori
authors.forename: Eri
authors.initials: E
authors.lastname: Sato
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Katsumata
authors.forename: Takahisa
authors.initials: T
authors.lastname: Gono
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kawaguchi
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Harigai
authors.forename: Hisashi
authors.initials: H
authors.lastname: Yamanaka
authors.forename: Jun
authors.initials: J
authors.lastname: Ishigooka
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D017668:Age of Onset; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced* / Q000175:diagnosis*; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones